company background image
ATRS

Antares PharmaNasdaqCM:ATRS Stock Report

Market Cap

US$635.7m

7D

6.1%

1Y

44.5%

Updated

23 Sep, 2021

Data

Company Financials +
ATRS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance5/6
Financial Health5/6
Dividends0/6

ATRS Overview

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.

Antares Pharma Competitors

Pfizer

NYSE:PFE

US$246.4b

Eli Lilly

NYSE:LLY

US$207.0b

Bristol-Myers Squibb

NYSE:BMY

US$133.7b

Viatris

NasdaqGS:VTRS

US$16.0b

Price History & Performance

Summary of all time highs, changes and price drops for Antares Pharma
Historical stock prices
Current Share PriceUS$3.83
52 Week HighUS$2.63
52 Week LowUS$5.07
Beta1.48
1 Month Change-3.28%
3 Month Change-11.75%
1 Year Change44.53%
3 Year Change13.99%
5 Year Change116.38%
Change since IPO-21.44%

Recent News & Updates

Shareholder Returns

ATRSUS PharmaceuticalsUS Market
7D6.1%0.2%-0.5%
1Y44.5%15.5%37.5%

Return vs Industry: ATRS exceeded the US Pharmaceuticals industry which returned 13.8% over the past year.

Return vs Market: ATRS exceeded the US Market which returned 36.2% over the past year.

Price Volatility

Is ATRS's price volatile compared to industry and market?
ATRS volatility
ATRS Beta1.48
Industry Beta0.64
Market Beta1

Stable Share Price: ATRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ATRS's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1978185Bob Applehttps://www.antarespharma.com

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate.

Antares Pharma Fundamentals Summary

How do Antares Pharma's earnings and revenue compare to its market cap?
ATRS fundamental statistics
Market CapUS$635.68m
Earnings (TTM)US$64.60m
Revenue (TTM)US$171.20m

10.1x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATRS income statement (TTM)
RevenueUS$171.20m
Cost of RevenueUS$68.46m
Gross ProfitUS$102.74m
ExpensesUS$38.14m
EarningsUS$64.60m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.39
Gross Margin60.01%
Net Profit Margin37.73%
Debt/Equity Ratio19.8%

How did ATRS perform over the long term?

See historical performance and comparison

Valuation

Is Antares Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ATRS ($3.83) is trading below our estimate of fair value ($18.49)

Significantly Below Fair Value: ATRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ATRS is good value based on its PE Ratio (10.1x) compared to the US Pharmaceuticals industry average (22x).

PE vs Market: ATRS is good value based on its PE Ratio (10.1x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

PEG Ratio: ATRS is good value based on its PEG Ratio (0.4x)


Price to Book Ratio

PB vs Industry: ATRS is overvalued based on its PB Ratio (4.9x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

28.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATRS's forecast earnings growth (28.4% per year) is above the savings rate (2%).

Earnings vs Market: ATRS's earnings (28.4% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ATRS's revenue (14.1% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: ATRS's revenue (14.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATRS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Antares Pharma performed over the past 5 years?

76.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRS has a high level of non-cash earnings.

Growing Profit Margin: ATRS's current net profit margins (37.7%) are higher than last year (4%).


Past Earnings Growth Analysis

Earnings Trend: ATRS has become profitable over the past 5 years, growing earnings by 76.3% per year.

Accelerating Growth: ATRS's earnings growth over the past year (1062.4%) exceeds its 5-year average (76.3% per year).

Earnings vs Industry: ATRS earnings growth over the past year (1062.4%) exceeded the Pharmaceuticals industry 17.5%.


Return on Equity

High ROE: ATRS's Return on Equity (48.9%) is considered outstanding.


Financial Health

How is Antares Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ATRS's short term assets ($128.0M) exceed its short term liabilities ($72.0M).

Long Term Liabilities: ATRS's short term assets ($128.0M) exceed its long term liabilities ($8.6M).


Debt to Equity History and Analysis

Debt Level: ATRS's debt to equity ratio (19.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ATRS's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ATRS's debt is well covered by operating cash flow (78.3%).

Interest Coverage: ATRS's interest payments on its debt are well covered by EBIT (6.3x coverage).


Balance Sheet


Dividend

What is Antares Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Bob Apple (55 yo)

5.67yrs

Tenure

US$3,753,646

Compensation

Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc....


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD3.75M) is above average for companies of similar size in the US market ($USD2.35M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ATRS's management team is considered experienced (4.9 years average tenure).


Board Members

Experienced Board: ATRS's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Company Information

Antares Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Antares Pharma, Inc.
  • Ticker: ATRS
  • Exchange: NasdaqCM
  • Founded: 1978
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$635.679m
  • Shares outstanding: 169.97m
  • Website: https://www.antarespharma.com

Number of Employees


Location

  • Antares Pharma, Inc.
  • 100 Princeton South
  • Suite 300
  • Ewing
  • New Jersey
  • 8628
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 22:59
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.